Pharmacotherapy for Irritable Bowel Syndrome
AbstractIrritable bowel syndrome (IBS) is a disorder of the brain-gut axis; the pathophysiological mechanisms include altered colonic motility, bile acid metabolism, neurohormonal regulation, immune dysfunction, alterations in the epithelial barrier and secretory properties of the gut. This article reviews the mechanisms, efficacy, and safety of current pharmacotherapy, and medications that are in phase III trials for the treatment of IBS. There remains a significant unmet need for effective treatments—particularly for the pain component of IBS—although the introduction of drugs directed at secretion, motility and a non-absorbable antibiotic provide options for the bowel dysfunction in IBS. View Full-Text
Share & Cite This Article
Camilleri, M.; Ford, A.C. Pharmacotherapy for Irritable Bowel Syndrome. J. Clin. Med. 2017, 6, 101.
Camilleri M, Ford AC. Pharmacotherapy for Irritable Bowel Syndrome. Journal of Clinical Medicine. 2017; 6(11):101.Chicago/Turabian Style
Camilleri, Michael; Ford, Alexander C. 2017. "Pharmacotherapy for Irritable Bowel Syndrome." J. Clin. Med. 6, no. 11: 101.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.